Biochemical Engineering
AbbVie acquires DJS Antibodies
20th October 2022
AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). Source: BIA News 20/10/2022
Back to group news